Lu Zheng1, Babafemi Taiwo, Rajesh T Gandhi, Peter W Hunt, Ann C Collier, Charles Flexner, Ronald J Bosch. 1. *Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA; †Division of Infectious Diseases, Northwestern University, Chicago, IL; ‡Division of Infectious Diseases, Massachusetts General Hospital (MGH), Boston, MA; §The Ragon Institute of MGH, Massachusetts Institute of Technology, and Harvard, Cambridge, MA; ‖Division of HIV/AIDS, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA; ¶Division of Infectious Diseases; Department of Medicine; University of Washington, Seattle, WA; #Division of Clinical Pharmacology, School of Medicine, Johns Hopkins University, Baltimore, MD; and **Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA.
Abstract
BACKGROUND:Abnormal levels of CD8 T-cell activation persist in HIV-1-infected patients on suppressive antiretroviral therapy (ART) and may be deleterious. METHODS:CD8 T-cell activation (% coexpressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infected patients on ART for ≥96 weeks with concurrent plasma HIV RNA (vRNA) ≤200 copies per milliliter. Factors associated with CD8 T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). RESULTS:Participants were 84% men, 47% white, 28% black, and 22% Hispanic, with median pre-ART age 38 years and median ART exposure 144 weeks. CD8 T-cell activation was higher at timepoints when vRNA was 51-200 versus ≤50 copies per milliliter [mean CD8 T-cell activation 23.4% vs. 19.7%; adjusted difference: 1.7% (95% confidence interval: 0.1 to 3.4), P = 0.042]. Restricting to vRNA ≤50 copies per milliliter, multivariable models showed the following factors associated with higher CD8 T-cell activation: older age [≥45 vs. ≤30 years: 3.6% (1.4 to 5.7), P = 0.004], hepatitis C virus antibody positivity [3.6% (0.9 to 6.2), P = 0.032], Hispanic vs. white [7.2% (5.3 to 9.0), P < 0.001], lower concurrent CD4 count [≤200 vs. >500 cells/mm: 2.2% (0.7 to 3.7), P < 0.001], lower concurrent CD4/CD8 ratio [-2.6% (-3.7 to -1.5) per 0.5 unit increase, P < 0.001], and higher pre-ART CD8 T-cell activation [2.0% (1.6 to 2.5) per 10% higher, P < 0.001]. CONCLUSIONS: In participants included in our analysis, residual low-level viremia between 51 and 200 copies per milliliter during ART was shown to be associated with greater CD8 T-cell activation than full suppression to <50 copies per milliliter. Older age, hepatitis C virus antibody positivity, race/ethnicity, higher pre-ART CD8 T-cell activation, and lower concurrent CD4/CD8 ratio and CD4 T-cell count also contribute to greater CD8 T-cell activation during suppressive ART.
RCT Entities:
BACKGROUND: Abnormal levels of CD8 T-cell activation persist in HIV-1-infectedpatients on suppressive antiretroviral therapy (ART) and may be deleterious. METHODS:CD8 T-cell activation (% coexpressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infectedpatients on ART for ≥96 weeks with concurrent plasma HIV RNA (vRNA) ≤200 copies per milliliter. Factors associated with CD8 T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). RESULTS:Participants were 84% men, 47% white, 28% black, and 22% Hispanic, with median pre-ART age 38 years and median ART exposure 144 weeks. CD8 T-cell activation was higher at timepoints when vRNA was 51-200 versus ≤50 copies per milliliter [mean CD8 T-cell activation 23.4% vs. 19.7%; adjusted difference: 1.7% (95% confidence interval: 0.1 to 3.4), P = 0.042]. Restricting to vRNA ≤50 copies per milliliter, multivariable models showed the following factors associated with higher CD8 T-cell activation: older age [≥45 vs. ≤30 years: 3.6% (1.4 to 5.7), P = 0.004], hepatitis C virus antibody positivity [3.6% (0.9 to 6.2), P = 0.032], Hispanic vs. white [7.2% (5.3 to 9.0), P < 0.001], lower concurrent CD4 count [≤200 vs. >500 cells/mm: 2.2% (0.7 to 3.7), P < 0.001], lower concurrent CD4/CD8 ratio [-2.6% (-3.7 to -1.5) per 0.5 unit increase, P < 0.001], and higher pre-ARTCD8 T-cell activation [2.0% (1.6 to 2.5) per 10% higher, P < 0.001]. CONCLUSIONS: In participants included in our analysis, residual low-level viremia between 51 and 200 copies per milliliter during ART was shown to be associated with greater CD8 T-cell activation than full suppression to <50 copies per milliliter. Older age, hepatitis C virus antibody positivity, race/ethnicity, higher pre-ARTCD8 T-cell activation, and lower concurrent CD4/CD8 ratio and CD4 T-cell count also contribute to greater CD8 T-cell activation during suppressive ART.
Authors: Alan L Landay; John Spritzler; Harold Kessler; Donna Mildvan; Minya Pu; Larry Fox; Dorothy O'Neil; Barbara Schock; Daniel Kuritzkes; Michael M Lederman Journal: J Infect Dis Date: 2003-11-13 Impact factor: 5.226
Authors: Margaret A Fischl; Heather J Ribaudo; Ann C Collier; Alejo Erice; Marina Giuliano; Marjorie Dehlinger; Joseph J Eron; Michael S Saag; Scott M Hammer; Stefano Vella; Gene D Morse; Judith E Feinberg; Lisa M Demeter; Susan H Eshleman Journal: J Infect Dis Date: 2003-08-15 Impact factor: 5.226
Authors: Kathleen A McGinnis; Michael J Fine; Ravi K Sharma; Melissa Skanderson; Joseph H Wagner; Maria C Rodriguez-Barradas; Linda Rabeneck; Amy C Justice Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: Jose M Benito; Mariola Lopez; Sara Lozano; Celia Ballesteros; Laura Capa; Pilar Martinez; Juan Gonzalez-Lahoz; Vincent Soriano Journal: J Infect Dis Date: 2005-12-15 Impact factor: 5.226
Authors: H Valdez; D Anthony; F Farukhi; A Patki; J Salkowitz; P Heeger; D L Peterson; A B Post; R Asaad; M M Lederman Journal: AIDS Date: 2000-10-20 Impact factor: 4.177
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Hernan Valdez; Elizabeth Connick; Kimberly Y Smith; Michael M Lederman; Ronald J Bosch; Ryung S Kim; Marty St Clair; Daniel R Kuritzkes; Harold Kessler; Lawrence Fox; Michelle Blanchard-Vargas; Alan Landay Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Robert C Kalayjian; Alan Landay; Richard B Pollard; Dennis D Taub; Barry H Gross; Isaac R Francis; Anne Sevin; Minya Pu; John Spritzler; Miriam Chernoff; Ann Namkung; Lawrence Fox; Ana Martinez; Karen Waterman; Susan A Fiscus; Beverly Sha; Debra Johnson; Stanley Slater; Frank Rousseau; Michael M Lederman Journal: J Infect Dis Date: 2003-05-29 Impact factor: 5.226
Authors: Massimo Andreoni; Sergio Babudieri; Savino Bruno; Massimo Colombo; Anna L Zignego; Vito Di Marco; Giovanni Di Perri; Carlo F Perno; Massimo Puoti; Gloria Taliani; Erica Villa; Antonio Craxì Journal: Infection Date: 2017-11-02 Impact factor: 3.553
Authors: Uma Shanmugasundaram; J William Critchfield; Linda C Giudice; Karen Smith-McCune; Ruth M Greenblatt; Barbara L Shacklett Journal: Am J Reprod Immunol Date: 2020-05-08 Impact factor: 3.886
Authors: Ramy El-Diwany; Florian P Breitwieser; Mary Soliman; Alyza M Skaist; Geetha Srikrishna; Joel N Blankson; Stuart C Ray; Sarah J Wheelan; David L Thomas; Ashwin Balagopal Journal: AIDS Date: 2017-06-19 Impact factor: 4.177
Authors: F De Salvador-Guillouët; C Sakarovitch; J Durant; K Risso; E Demonchy; P M Roger; E Fontas Journal: PLoS One Date: 2015-10-20 Impact factor: 3.240
Authors: Mark H Kuniholm; Thomas R OʼBrien; Ludmila Prokunina-Olsson; Michael Augenbraun; Michael Plankey; Roksana Karim; Monika Sarkar; Audrey L French; Chris Pierce; Howard D Strickler; Kathryn Anastos Journal: J Acquir Immune Defic Syndr Date: 2016-06-01 Impact factor: 3.731